

Press Release

For Immediate Dissemination

Glenmark appoints Dr. Kurt Stoeckli as President and Chief Scientific Officer

- Dr. Stoeckli will oversee Glenmark's entire research portfolio including biologics (NBEs) and small molecules (NCEs)

Mumbai, India; October 13, 2016: Glenmark today announced the appointment of Dr. Kurt Stoeckli as President and Chief Scientific Officer (CSO). Dr. Stoeckli joins Glenmark from SANOFI where he was Group Vice President, Global Biopharmaceuticals Division & Chief Scientific Officer for R&D France. He will report to Glenn Saldanha, Chairman and MD and will be based out of Neuchâtel, Switzerland. He will also be President and General Manager of Glenmark's Switzerland-based business units.

Dr. Stoeckli will lead the company's global research portfolio consisting of NBE, NCE, generics and branded formulations. He will be responsible for sustaining and enhancing the environment of collaborative research and for driving successful commercialization of Glenmark's research pipeline in partnership with other leaders.

"We are pleased to bring Dr. Stoeckli's expertise to Glenmark which will further drive the advancement of our new molecular entity portfolio and enable us to continue discovering NMEs both small molecules and biologics," said Glenn Saldanha, Chairman and MD, Glenmark Pharmaceuticals Ltd. "Dr. Stoeckli's invaluable scientific knowledge and leadership will enable us to achieve our goal of becoming a global innovative pharmaceutical organisation."

Having spent more than two decades in the pharmaceutical industry, Dr. Stoeckli has an extensive industry experience in driving biologics from early research up to phase 3. He has played a pivotal role in fostering and managing Sanofi's JV with Regeneron Pharmaceuticals Inc. During his 15 year tenure at Sanofi, he was a member of global R&D board and held global leadership positions as Head of the Therapeutic Unit Immunology & Inflammation, VP Biological Sciences & Scientific Site Director of the R&D Centre in Paris-Vitry (France) and VP Lead Discovery for small molecules research, based in Frankfurt (Germany).

Dr. Stoeckli's achievements include the successful leadership of scientific teams responsible for discovery and development of both NBEs and NCEs. Under his leadership, more than 20 projects advanced to clinical stage (ranging from Ph1 through Ph3) in the areas of autoimmune and inflammatory disorders, and oncology.

Graduating from the Biocenter of University of Basel, ETH Zurich and Max-Planck-Institute (Munich), Dr. Stoeckli was a Postdoctoral Fellow and Assistant Professor at the Department of Biochemistry & Biophysics, University of California Medical Center (UCSF) before he started his career in industry at Novartis/Sandoz Pharma AG in Basel, Switzerland.

Glenmark's previous President and CSO, Dr. Michael Buschle, will have a new role as Chief Scientific Mentor and will continue to provide strategic and scientific direction to Glenmark's Worldwide Drug Discovery Programs and pharmaceutical development. Dr. Buschle will work directly with Mr. Glenn Saldanha.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2016). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in the branded generics markets across emerging economies including India. GPL along with its subsidiaries operate 17 manufacturing facilities across four countries and has five R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Ramkumar Uppara/Shibani Shah

Glenmark, Mumbai, India

Tel: [+91 22] 4018 9984/9348

Email: corpcomm@glenmarkpharma.com